Literature DB >> 17959847

Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques.

L E Pereira1, F Villinger, H Wulff, A Sankaranarayanan, G Raman, A A Ansari.   

Abstract

The small molecule 5-(4-phenoxybutoxy)psoralen (PAP-1) is a selective blocker of the voltage-gated potassium channel Kv1.3 that is highly expressed in cell membranes of activated effector memory T cells (TEMs). The blockade of Kv1.3 results in membrane depolarization and inhibition of TEM proliferation and function. In this study, the in vitro effects of PAP-1 on T cells and the in vivo toxicity and pharmacokinetics (PK) were examined in rhesus macaques (RM) with the ultimate aim of utilizing PAP-1 to define the role of TEMs in RM infected with simian immunodeficiency virus (SIV). Electrophysiologic studies on T cells in RM revealed a Kv1.3 expression pattern similar to that in human T cells. Thus, PAP-1 effectively suppressed TEM proliferation in RM. When administered intravenously, PAP-1 showed a half-life of 6.4 hrs; the volume of distribution suggested extensive distribution into extravascular compartments. When orally administered, PAP-1 was efficiently absorbed. Plasma concentrations in RM undergoing a 30-day, chronic dosing study indicated that PAP-1 levels suppressive to TEMs in vitro can be achieved and maintained in vivo at a non-toxic dose. PAP-1 selectively inhibited the TEM function in vivo, as indicated by a modest reactivation of cytomegalovirus (CMV) replication. Immunization of these chronically treated RM with the live influenza A/PR8 (flu) virus suggested that the development of an in vivo, flu-specific, central memory response was unaffected by PAP-1. These RM remained disease-free during the entire course of the PAP-1 study. Collectively, these data provide a rational basis for future studies with PAP-1 in SIV-infected RM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17959847      PMCID: PMC2390884          DOI: 10.3181/0705-RM-148

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  44 in total

1.  Failure to expand influenza and tetanus toxoid memory T cells in vitro correlates with disease course in SIV infected rhesus macaques.

Authors:  A A Ansari; P Bostik; A E Mayne; F Villinger
Journal:  Cell Immunol       Date:  2001-06-15       Impact factor: 4.868

2.  K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity.

Authors:  Heike Wulff; Hans-Günther Knaus; Michael Pennington; K George Chandy
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

3.  Disseminated cytomegalovirus infection in immunodeficient rhesus monkeys.

Authors:  G B Baskin
Journal:  Am J Pathol       Date:  1987-11       Impact factor: 4.307

4.  Decreased frequency of cytomegalovirus (CMV)-specific CD4+ T lymphocytes in simian immunodeficiency virus-infected rhesus macaques: inverse relationship with CMV viremia.

Authors:  Amitinder Kaur; Corrina L Hale; Bradley Noren; Nadine Kassis; Meredith A Simon; R Paul Johnson
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

5.  Subset-specific expression of potassium channels in developing murine T lymphocytes.

Authors:  R S Lewis; M D Cahalan
Journal:  Science       Date:  1988-02-12       Impact factor: 47.728

6.  Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.

Authors:  Alexander Schmitz; Ananthakrishnan Sankaranarayanan; Philippe Azam; Kristina Schmidt-Lassen; Daniel Homerick; Wolfram Hänsel; Heike Wulff
Journal:  Mol Pharmacol       Date:  2005-08-11       Impact factor: 4.436

7.  Cytotoxic T-lymphocyte responses to cytomegalovirus in normal and simian immunodeficiency virus-infected rhesus macaques.

Authors:  A Kaur; M D Daniel; D Hempel; D Lee-Parritz; M S Hirsch; R P Johnson
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

8.  Characterization of subsets of CD4+ memory T cells reveals early branched pathways of T cell differentiation in humans.

Authors:  Kaimei Song; Ronald L Rabin; Brenna J Hill; Stephen C De Rosa; Stephen P Perfetto; Hongwei H Zhang; John F Foley; Jeffrey S Reiner; Jie Liu; Joseph J Mattapallil; Daniel C Douek; Mario Roederer; Joshua M Farber
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-19       Impact factor: 11.205

9.  Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.

Authors:  Christine Beeton; Heike Wulff; Nathan E Standifer; Philippe Azam; Katherine M Mullen; Michael W Pennington; Aaron Kolski-Andreaco; Eric Wei; Alexandra Grino; Debra R Counts; Ping H Wang; Christine J LeeHealey; Brian S Andrews; Ananthakrishnan Sankaranarayanan; Daniel Homerick; Werner W Roeck; Jamshid Tehranzadeh; Kimber L Stanhope; Pavel Zimin; Peter J Havel; Stephen Griffey; Hans-Guenther Knaus; Gerald T Nepom; George A Gutman; Peter A Calabresi; K George Chandy
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-06       Impact factor: 11.205

10.  Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia.

Authors:  Guido Silvestri; Donald L Sodora; Richard A Koup; Mirko Paiardini; Shawn P O'Neil; Harold M McClure; Silvija I Staprans; Mark B Feinberg
Journal:  Immunity       Date:  2003-03       Impact factor: 31.745

View more
  28 in total

1.  Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson's disease.

Authors:  Souvarish Sarkar; Hai M Nguyen; Emir Malovic; Jie Luo; Monica Langley; Bharathi N Palanisamy; Neeraj Singh; Sireesha Manne; Matthew Neal; Michelle Gabrielle; Ahmed Abdalla; Poojya Anantharam; Dharmin Rokad; Nikhil Panicker; Vikrant Singh; Muhammet Ay; Adhithiya Charli; Dilshan Harischandra; Lee-Way Jin; Huajun Jin; Srikant Rangaraju; Vellareddy Anantharam; Heike Wulff; Anumantha G Kanthasamy
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

2.  Identification of phase-I metabolites and chronic toxicity study of the Kv1.3 blocker PAP-1 (5-(4-phenoxybutoxy)psoralen) in the rat.

Authors:  B Hao; Z-W Chen; X-J Zhou; P I Zimin; G P Miljanich; H Wulff; Y-X Wang
Journal:  Xenobiotica       Date:  2010-11-11       Impact factor: 1.908

3.  4-Phenoxybutoxy-substituted heterocycles--a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3.

Authors:  Silke B Bodendiek; Cédrick Mahieux; Wolfram Hänsel; Heike Wulff
Journal:  Eur J Med Chem       Date:  2008-11-05       Impact factor: 6.514

4.  Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.

Authors:  M W Pennington; C Beeton; C A Galea; B J Smith; V Chi; K P Monaghan; A Garcia; S Rangaraju; A Giuffrida; D Plank; G Crossley; D Nugent; I Khaytin; Y Lefievre; I Peshenko; C Dixon; S Chauhan; A Orzel; T Inoue; X Hu; R V Moore; R S Norton; K G Chandy
Journal:  Mol Pharmacol       Date:  2009-01-02       Impact factor: 4.436

Review 5.  K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.

Authors:  Heike Wulff; Boris S Zhorov
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

6.  The small neurotoxin apamin blocks not only small conductance Ca2+ activated K+ channels (SK type) but also the voltage dependent Kv1.3 channel.

Authors:  Patrick Voos; Mehtap Yazar; René Lautenschläger; Oliver Rauh; Anna Moroni; Gerhard Thiel
Journal:  Eur Biophys J       Date:  2017-01-20       Impact factor: 1.733

7.  Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept.

Authors:  Izumi Maezawa; Hai M Nguyen; Jacopo Di Lucente; David Paul Jenkins; Vikrant Singh; Silvia Hilt; Kyoungmi Kim; Srikant Rangaraju; Allan I Levey; Heike Wulff; Lee-Way Jin
Journal:  Brain       Date:  2018-02-01       Impact factor: 13.501

8.  The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression.

Authors:  Jenny Lam; Heike Wulff
Journal:  Drug Dev Res       Date:  2011-11       Impact factor: 4.360

Review 9.  Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.

Authors:  Victor Chi; Michael W Pennington; Raymond S Norton; Eric J Tarcha; Luz M Londono; Brian Sims-Fahey; Sanjeev K Upadhyay; Jonathan T Lakey; Shawn Iadonato; Heike Wulff; Christine Beeton; K George Chandy
Journal:  Toxicon       Date:  2011-08-12       Impact factor: 3.033

Review 10.  Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies.

Authors:  Amos Gilhar; Adam G Schrum; Amos Etzioni; Herman Waldmann; Ralf Paus
Journal:  Autoimmun Rev       Date:  2016-03-10       Impact factor: 9.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.